Chemotherapy News and Research

Latest Chemotherapy News and Research

Oncology experts to discuss latest developments in head and neck cancers

The European Society for Therapeutic Radiology and Oncology (ESTRO), the European Head and Neck Society (EHNS), and the European Society for Medical Oncology (ESMO) in collaboration with other European partners, have the pleasure of inviting you to report on the 3rd International Conference on innovative approaches In Head and Neck Oncology that will be held in Barcelona (Spain) on the 24th -26th February 2011.

1 Feb 2011

Roundup: Tenn. community health centers feel budget pinch; Minn. faces struggles with costs of inmate care

Originally created to care for destitute urban dwellers or dirt-poor sharecroppers, health centers today serve a much wider segment of America. A prolonged recession and a shortage of primary care physicians have expanded their patient base. Going forward, they are expected to meet the needs of millions more Americans. But getting there could be a challenge.

1 Feb 2011

Yale University scientists synthesize lomaiviticin that appears to destroy cancer stem cells

A team of Yale University scientists has synthesized for the first time a chemical compound called lomaiviticin aglycon, leading to the development of a new class of molecules that appear to target and destroy cancer stem cells.

1 Feb 2011

Research on triple negative disease can benefit patients with breat cancer

Research to develop more effective treatments for triple negative breast cancer -- a difficult disease to cure -- could someday benefit all breast cancer patients, reports Dr. Frederick C. Tucker, Jr. of Fredericksburg Oncology.

1 Feb 2011

Simple hTERT analysis may provide useful prognostic tool in advanced non-small cell lung cancer

High levels of circulating DNA may indicate faster progression of lung cancer and lower overall survival, according to a study published in the February edition of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer (IASLC).

1 Feb 2011

FDA approves Boston Scientific's Renegade HI-FLO Fathom Pre-Loaded System

Boston Scientific Corporation today announced that the U.S. Food and Drug Administration has approved its Renegade HI-FLO Fathom Pre-Loaded System for selective access and delivery of diagnostic, embolic and therapeutic materials into the peripheral vasculature.

1 Feb 2011

Researchers to develop computer-assisted diagnosis tools for pathologists

Researchers are leveraging Ohio Supercomputer Center resources to develop computer-assisted diagnosis tools that will provide pathologists grading Follicular Lymphoma samples with quicker, more consistently accurate diagnoses.

31 Jan 2011

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the initiation of two studies to further evaluate the efficacy and safety of VB-111 in advanced cancers.

31 Jan 2011

New study: FUS protein appears to inhibit growth of prostate cancer cells in lab

Cancer researchers have discovered an important protein, produced naturally inside cells, that appears to suppress the growth of prostate cancer cells in the laboratory. The findings, published tomorrow in the journal Cancer Research, offer promising leads for research towards new treatments.

31 Jan 2011

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Inovio Pharmaceuticals, a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today the regulatory approval of a Phase 2 clinical trial to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device.

31 Jan 2011

Extreme morning sickness drug comes at a price

Women, who suffer from an extreme form of morning sickness called hyperemesis gravidarum (HG), are shelling out $7,000 for a drug not yet approved for use by expectant mums because they are desperate to control their illness. HG leads to severe nausea, dehydration and fatigue and may require hospitalization. It affects up to 3 per cent of pregnant women - about 9,000 per year in Australia. It may lead to termination of the pregnancy.

31 Jan 2011

EVP of Advaxis' Science & Operations moderates Live Cancer Vaccines panel discussion

Dr. John Rothman, EVP of Science & Operations of Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, moderated a panel discussion titled, "Live Cancer Vaccines."

29 Jan 2011

Light therapy can help preserve vocal cord function for patients with early stage laryngeal cancer: Study

Light, or photodynamic, therapy can help preserve the voice and vocal cord function for patients with early stage laryngeal (voice box) cancer, according to a study from Henry Ford Hospital in Detroit.

29 Jan 2011

New surgical approach can remove throat tumor and rebuild trachea

Using a novel surgical approach, it's possible to rebuild the trachea and preserve a patient's voice after removing an invasive throat tumor, according to a new report from Henry Ford Hospital in Detroit.

29 Jan 2011

Genentech, Biogen announce FDA approval of Rituxan to treat follicular lymphoma

Genentech, a member of the Roche Group, and Biogen Idec today announced the U.S. Food and Drug Administration approved Rituxan as a maintenance treatment for patients with advanced follicular lymphoma who responded to initial treatment with Rituxan plus chemotherapy.

28 Jan 2011

Survey finds public lack knowledge of radiotherapy

Fewer than one in ten people think radiotherapy is a modern cancer treatment according to the results of a survey published Friday.

28 Jan 2011

Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint

Genentech, a member of the Roche Group and OSI Pharmaceuticals, a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc., today announced that an independent data monitoring committee has recommended that the Phase III EURTAC study be stopped early because the study met its primary endpoint.

28 Jan 2011

Prototype drug halts GVHD in mouse models of bone marrow transplantation

A prototype drug already shown to hold promise for treating autoimmune disorders like lupus, arthritis and psoriasis halts established graft-versus-host disease (GVHD) in mouse models of bone marrow transplantation, research at the University of Michigan and the University of Florida shows.

28 Jan 2011

Study suggests newborn diagnosis can improve survival in SCID patients

Severe Combined Immunodeficiency occurs in just one out of every 50,000 to 100,000 births in the United States, yet it is the most serious primary immunodeficiency disorder. A study published today in Blood, the Journal of the American Society of Hematology, demonstrates that babies with SCID who are diagnosed at birth and receive a hematopoietic stem cell transplant, which is the transplantation of blood-forming stem cells, have significantly improved survival.

28 Jan 2011

XYTOS shares cancer patient treatment results

XYTOS Shares Patient Results.

28 Jan 2011

Chemotherapy News and Research

Latest Chemotherapy News and Research

Oncology experts to discuss latest developments in head and neck cancers

Roundup: Tenn. community health centers feel budget pinch; Minn. faces struggles with costs of inmate care

Yale University scientists synthesize lomaiviticin that appears to destroy cancer stem cells

Research on triple negative disease can benefit patients with breat cancer

Simple hTERT analysis may provide useful prognostic tool in advanced non-small cell lung cancer

FDA approves Boston Scientific's Renegade HI-FLO Fathom Pre-Loaded System

Researchers to develop computer-assisted diagnosis tools for pathologists

VBL commences two studies to evaluate efficacy, safety of VB-111 in advanced cancers

New study: FUS protein appears to inhibit growth of prostate cancer cells in lab

Inovio announces regulatory approval for Phase 2 trial to treat leukemia using new vaccine delivery device

Extreme morning sickness drug comes at a price

EVP of Advaxis' Science & Operations moderates Live Cancer Vaccines panel discussion

Light therapy can help preserve vocal cord function for patients with early stage laryngeal cancer: Study

New surgical approach can remove throat tumor and rebuild trachea

Genentech, Biogen announce FDA approval of Rituxan to treat follicular lymphoma

Survey finds public lack knowledge of radiotherapy

Tarceva Phase III EURTAC study in NSCLC patients with EGFR activating mutations meets primary endpoint

Prototype drug halts GVHD in mouse models of bone marrow transplantation

Study suggests newborn diagnosis can improve survival in SCID patients

XYTOS shares cancer patient treatment results

Cancer Research - Second Edition eBook

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Edoardo Fabini

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Transforming Lab Workflows with Cell Culture Automation

Building Bridges to Scalable Allogeneic Cell Therapy

Edoardo Fabini

Newsletters you may be interested in